Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist.
PGU Cardiovascular Research, Cassella AG-Hoechst AG, Frankfurt/M., F.R.G.
P A
PA
Martorana
B
B
Kettenbach
G
G
Breipohl
W
W
Linz
B A
BA
Schölkens
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001920:Bradykinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000031:analogs & derivatives; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D009842:Oligopeptides / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology; D017257:Ramipril / Q000031:analogs & derivatives*
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D011758:Pyrroles; C052549:ramiprilat; C065679:icatibant; D017257:Ramipril; D001920:Bradykinin